Mantle Cell Lymphoma
News
Ibrutinib approved for mantle cell lymphoma
News
FDA approves lenalidomide for mantle cell lymphoma
Conference Coverage
'Highest response rate ever reported' in relapsed mantle cell lymphoma
Major Finding: In an efficacy cohort of 110 patients with relapsed or refractory mantle cell lymphoma, 22% had a complete response and 46% a...
Conference Coverage
CNS Events Not Immediately Fatal in Mantle Cell Lymphomas
Major Finding: Crude prevalences of CNS involvement at diagnosis and overall were 0.9% and 4.1%, respectively, with a median time to an event of...